Lake Street lowered the firm's price target on Tela Bio to $2 from $3 and keeps a Buy rating on the shares following an "approximately in line" Q4 and reset of 2026 guidance. The company now guides to 8% top line growth, versus the previous 15% growth expectation introduced with Q3 results, notes the analyst, who says shares "remain in show me territory."
